Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.

@article{Liang2018EfficacyOA,
  title={Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.},
  author={M. -Z. Liang and Shicheng Yang and Naikuan Fu and Chengzhi Lu and Fengshi Tian and Xiaochun Xing and Wenhua Lin and Jingjing Liu},
  journal={Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions},
  year={2018},
  volume={91 4},
  pages={742-750}
}
BACKGROUND The role of alprostadil on the prevention of contrast-induced nephropathy (CIN) still remains controversial. The purpose of this study was to examine the effects of short-term alprostadil on the incidence of CIN in patients undergoing elective percutaneous coronary intervention (PCI). METHODS A total of 480 patients with coronary heart disease… CONTINUE READING